skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Update on options for treatment of metastatic castration-resistant prostate cancer

Review

(3250) Views  (1332) Full article downloads

Authors: Prakash Vishnu, Winston W Tan

Published Date March 2010 Volume 2010:3 Pages 39 - 51
DOI: http://dx.doi.org/10.2147/OTT.S5818

Prakash Vishnu, Winston W Tan

Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL, USA

Background: Prostate cancer is one of the most common cancers in men in US and European countries. Despite having a favorable prognosis, the incidence of incurable metastatic disease and mortality in the US is about 28,000 per year. Although hormone-based androgen deprivation therapies typically result in rapid responses, nearly all patients eventually develop progressive castration-resistant disease state. With readily available prostate-specific antigen (PSA) testing, most of these patients are asymptomatic and manifest progression simply as a rising PSA. In patients with castration-resistant prostate cancer (CRPC), the median survival is about 1–2 years, with improvements in survival seen mostly with docetaxel-based regimens. The purpose of this article is to review the recent developments in the treatment of advanced CRPC.

Recent findings: Since the two landmark trials (TAX-327 and Southwest Oncology Group 99–16) in CRPC, several newer cytotoxic drugs (epothilones, satraplatin), targeted agents (abiraterone, MDV3100) and vaccines have been tested in phase II and III setting with promising results.

Conclusions: The role of newer agents in the treatment of CRPC still needs to be validated by phase III trials, which are currently ongoing. Whilst the novel biomarkers, ‘circulating tumor cells’, have been shown to provide important prognostic information and are anticipated to be incorporated in future clinical decision-making, their exact utility and relevance calls for a larger prospective validation.

Keywords: castration-resistant prostate cancer, novel therapies, mechanisms of resistance, circulating tumor cells






 

Other articles by Dr Winston Tan



Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
CTLA-4 blockade: therapeutic potential in cancer treatments
Current and emerging therapies for the treatment of pancreatic cancer
Colonic polyps: inheritance, susceptibility, risk evaluation, and diagnostic management
An update on TroVax® for the treatment of progressive castration-resistant prostate cancer
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
Erratum
Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature